Results 141 to 150 of about 1,925 (192)

Safety and Pharmacokinetics of Nirsevimab in Japanese Infants: Primary Analysis of the Open-Label JUBILUS Trial. [PDF]

J Pediatric Infect Dis Soc
Mori M, Leach S, Learoyd M, Vijapur D, Sadow S, Wilkins D, Abe Y, Ikeda K, Kanegane H, Kano Z, Moriuchi H, Muneuchi J, Nishikomori R, Okazaki K, Takas T, Sakaguchi A, Villafana T.   +16 more
europepmc   +1 more source

Nirsevimab in Infants: The Cost of Changing the Paradigm

Mathews Journal of Pediatrics
openaire   +1 more source

Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus-Related Hospitalization in Newborns.

JAMA
Jabagi MJ, Bertrand M, Gabet A, Kolla E, Olié V, Zureik M.   +5 more
europepmc   +1 more source

Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity

New England Journal of Medicine, 2022
The efficacy and safety of nirsevimab in the treatment of medically attended respiratory syncytial virus (RSV) infections of the lower respiratory tract in otherwise healthy, late preterm and term infants were assessed in the phase 2B1 and phase 3 ...
Joseph B Domachowske, Shabir A Madhi, Amanda Leach   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Formulary Drug Reviews: Nirsevimab

Hospital Pharmacy, 2023
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Terri L. Levien, Danial E. Baker
openaire   +2 more sources

Nirsevimab: First Approval

Drugs, 2022
Nirsevimab (Beyfortus®), a long-acting intramuscular recombinant neutralising human IgG1ĸ monoclonal antibody to the prefusion conformation of the respiratory syncytial virus (RSV) F protein that has been modified with a triple amino acid substitution in the Fc region to extend the serum half-life, is being jointly developed by AstraZeneca and Sanofi ...
openaire   +2 more sources

Nirsevimab and Hospitalization for RSV Bronchiolitis

New England Journal of Medicine
Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis, resulting in 3 million hospitalizations each year worldwide. Nirsevimab is a monoclonal antibody against RSV that has an extended half-life. Its postlicensure real-world effectiveness against RSV-associated bronchiolitis is unclear.We conducted a prospective, multicenter, matched ...
Assad, Zein, Romain, Anne-Sophie, Aupiais, Camille, Shum, Mickaël, Schrimpf, Cécile, Lorrot, Mathie, Corvol, Harriet, Prevost, Blandine, Ferrandiz, Charlène, Giolito, Anna, Valtuille, Zaba, Bendavid, Matthieu, Cohen, Jérémie, Toubiana, Julie, de Pontual, Loïc, Delande, Camille, Levy, Michael, See, Perrine, Cohen, Robert, Levy, Corinne, Angoulvant, François, Lenglart, Léa, Gits-Muselli, Maud, Biran, Valérie, Diallo, Kadiatou, Alemede, Oluwafunmilola, El Hebil, Mohamed, Durrmeyer, Xavier, Labouret, Géraldine, Casanovas, Natacha, Hallak, Benjamin, Maréchal, Olympe, Jung, Camille, Bréhin, Camille, Ouldali, Naïm   +34 more
openaire   +2 more sources